Fresenius Medical Care (NYSE:FMS) Shares Gap Down to $20.54

Fresenius Medical Care AG (NYSE:FMS - Get Free Report)'s share price gapped down prior to trading on Thursday . The stock had previously closed at $20.54, but opened at $20.03. Fresenius Medical Care shares last traded at $19.90, with a volume of 34,753 shares trading hands.

Analysts Set New Price Targets

A number of research firms have weighed in on FMS. Truist Financial decreased their price target on Fresenius Medical Care from $24.00 to $22.00 and set a "hold" rating for the company in a research note on Wednesday, July 31st. StockNews.com began coverage on Fresenius Medical Care in a research note on Friday, September 6th. They issued a "strong-buy" rating for the company. One analyst has rated the stock with a sell rating, three have given a hold rating, one has issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Fresenius Medical Care presently has a consensus rating of "Hold" and a consensus price target of $22.00.

Fresenius Medical Care Price Performance

The stock has a market capitalization of $11.84 billion, a price-to-earnings ratio of 22.62, a PEG ratio of 1.05 and a beta of 0.90. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.09 and a current ratio of 1.46. The company has a fifty day simple moving average of $19.40 and a two-hundred day simple moving average of $19.87.

Fresenius Medical Care (NYSE:FMS - Get Free Report) last announced its quarterly earnings data on Tuesday, July 30th. The company reported $0.38 earnings per share for the quarter, meeting the consensus estimate of $0.38. The firm had revenue of $5.13 billion during the quarter, compared to analysts' expectations of $5.28 billion. Fresenius Medical Care had a return on equity of 5.48% and a net margin of 2.72%. As a group, equities research analysts expect that Fresenius Medical Care AG will post 1.51 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Fresenius Medical Care

A number of institutional investors have recently modified their holdings of the business. Assetmark Inc. increased its holdings in Fresenius Medical Care by 169.9% in the 4th quarter. Assetmark Inc. now owns 4,178 shares of the company's stock worth $87,000 after purchasing an additional 2,630 shares in the last quarter. GAMMA Investing LLC increased its holdings in Fresenius Medical Care by 21.8% in the 1st quarter. GAMMA Investing LLC now owns 4,230 shares of the company's stock worth $82,000 after purchasing an additional 758 shares in the last quarter. ORG Partners LLC acquired a new position in Fresenius Medical Care in the 1st quarter worth about $110,000. SageView Advisory Group LLC acquired a new position in Fresenius Medical Care in the 1st quarter worth about $127,000. Finally, Signaturefd LLC increased its holdings in Fresenius Medical Care by 8.4% in the 2nd quarter. Signaturefd LLC now owns 8,713 shares of the company's stock worth $166,000 after purchasing an additional 672 shares in the last quarter. Institutional investors and hedge funds own 8.25% of the company's stock.

Fresenius Medical Care Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.